Events

8th Metabolic Continuum Roundtable™ Annual Meeting – MASH Disease Monitoring and Treatment Decisions Using Non-Invasive Tests: Readiness of the NITs Toolbox
May, 2025 | Amsterdam, Netherlands
Contact Us »

7th Metabolic Continuum Roundtable™ Annual Meeting – Steatotic Liver Disease (MASLD/MASH): Disease Burden – Patient Reported Outcomes – Health Economics: Payor & Societal Perspectives
November 10, 2023 | Boston, MA
More Information »

6th NASH Roundtable™ Forum – Clinical Trials with Non-Invasive Tests (NITs) Instead of Histology: Fact or Fancy?
November 5, 2022 | Washington, DC
More information »

5th NASH Roundtable™ Virtual Forum – Is Digital Pathology a Game-Changer for Histology for NASH Drug Development?
June 16, 2022 | Virtual
More information »

Resources

Fact Sheet: Metabolic Continuum Roundtable™, leading clinical development experts addressing challenges in NASH drug development

View Fact Sheet »

Member Co-authored Publications

July 12, 2024

MASLD and MASH at the crossroads of hepatology trials and cardiorenal metabolic trials. Read More »

June 17, 2024

Is digital pathology the new standard in MASH trials? Read More »

June 12, 2024

An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD). Read More »

June 11, 2024

The fibroblast hormone endotrophin is a biomarker of mortality in chronic diseases. Read More »

June 10, 2024

Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Read More »

June 8, 2024

Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. Read More »